2022-501766-22-01招募中1 期
A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim RCV GmbH & Co. KG7 个研究点 分布在 4 个国家目标入组 14 人开始时间: 2024年4月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 14
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (7)
Loading locations...
相似试验
招募中
1 期
A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas2024-519301-36-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.40
招募中
1 期
A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)2024-511501-37-00Boehringer Ingelheim International GmbH18
招募中
1 期
A study to test how well different doses of BI 3804379 are tolerated by healthy people2024-513549-36-01Boehringer Ingelheim International GmbH106
招募中
1 期
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).2024-512504-19-00Boehringer Ingelheim International GmbH97
招募中
1 期
A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity2023-508767-79-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim International GmbH125